Welcome to STN International! Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Apr 08	"Ask CAS" for self-help around the clock
NEWS 3	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4	Apr 09	ZDB will be removed from STN
NEWS 5	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS 8	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS 9	Jun 03	New e-mail delivery for search results now available
NEWS 10	Jun 10	MEDLINE Reload
NEWS 11	Jun 10	PCTFULL has been reloaded
NEWS 12	Jul 02	FOREGE no longer contains STANDARDS file segment
NEWS 13	Jul 22	USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS 14	Jul 29	Enhanced polymer searching in REGISTRY
NEWS 15	Jul 30	NETFIRST to be removed from STN
NEWS 16	Aug 08	CANCERLIT reload
NEWS 17	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18	Aug 08	NTIS has been reloaded and enhanced
NEWS 19	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 20	Aug 19	IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21	Aug 19	The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 23	Sep 03	JAPIO has been reloaded and enhanced
NEWS 24	Sep 16	Experimental properties added to the REGISTRY file
NEWS 25	Sep 16	Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 26	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 27	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS 28	Oct 21	EVENTLINE has been reloaded
NEWS 29	Oct 24	BEILSTEIN adds new search fields
NEWS 30	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 31	Oct 25	MEDLINE SDI run of October 8, 2002
NEWS 32	Nov 18	DKILIT has been renamed APOLLIT

NEWS EXPRESS	October 14 CURRENT WINDOWS VERSION IS V6.01, CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP), AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items

NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:57:46 ON 24 NOV 2002

=> file medline, biosis, wpids, embase, dgene, uspatful

COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 15:58:08 ON 24 NOV 2002

FILE 'BIOSIS' ENTERED AT 15:58:08 ON 24 NOV 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'WPIDS' ENTERED AT 15:58:08 ON 24 NOV 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 15:58:08 ON 24 NOV 2002
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'DGENE' ENTERED AT 15:58:08 ON 24 NOV 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'USPATFULL' ENTERED AT 15:58:08 ON 24 NOV 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

=> s non-peptidyl compound

L1 50 NON-PEPTIDYL COMPOUND

=> s l1 and insulin

L2 23 L1 AND INSULIN

=> d l2 ti abs ibib tot

L2 ANSWER 1 OF 23 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
TI Anti-obesity and **insulin** sensitizing effects of small molecule **insulin** receptor activators.
ACCESSION NUMBER: 2001:458806 BIOSIS
DOCUMENT NUMBER: PREV200100458806
TITLE: Anti-obesity and **insulin** sensitizing effects of small molecule **insulin** receptor activators.
AUTHOR(S): Strowski, Mathias Z. (1); Air, Ellen; Salituro, Gino M.; Liu, Kun; Woods, Stephen C.; Zhang, Bei B.
CORPORATE SOURCE: (1) Rahway, NJ USA
SOURCE: Diabetes, (June, 2001) Vol. 50, No. Supplement 2, pp. A275.

print.
Meeting Info.: 61st Scientific Sessions of the American Diabetes Association Philadelphia, Pennsylvania, USA June 22-26, 2001
ISSN: 0012-1797.
DOCUMENT TYPE: Conference
LANGUAGE: English
SUMMARY LANGUAGE: English

L2 ANSWER 2 OF 23 WPIDS (C) 2002 THOMSON DERWENT
TI Use of non-peptide modulators of **insulin** action for treating e.g. diabetes mellitus, insulinomas, **insulin** and hyperglycemic drug overdose, gastric dumping syndrome and congenital hyperinsulinism.
AN 2000-338749 [29] WPIDS
AB WO 200016798 A UPAB: 20000617
NOVELTY - Use of non-peptidyl compounds which are biological modulators of **insulin** activity is disclosed.
DETAILED DESCRIPTION - A novel method for treating a patient suffering from one or more **insulin** related ailments comprises administering a compound that is a biological modulator of **insulin** activity, which compound possesses ionic and hydrophobic chemical moieties spatially located so as to mimic the spatial location of at least an ionic and hydrophobic amino acid residue of **insulin**, which amino acids are associated with the binding of **insulin** to its receptor.
INDEPENDENT CLAIMS are also included for:
(1) the use of at least a **non-peptidyl compound**, which is at least a biological modulator of **insulin** activity and possesses ionic and hydrophobic chemical moieties spatially located so as to mimic the spatial location at least an ionic and hydrophobic amino acid residue of **insulin**, which amino acids are associated with the binding of **insulin** to its receptor, in the preparation of a medicament for the treatment of a patient suffering from one or more **insulin** related ailments;
(2) a pharmaceutical composition comprising at least a chemical compound capable of modulating the biological activity of **insulin** and a carrier and/or diluent, where the compound has the following formula: AXYXZn (I);
A = W or VXW;
V = V1 or V2 and V is substituted with up to 2 X groups; ;
V1 = a phenyl or 6-membered heteroaromatic ring, optionally substituted with up to 5 R1 groups;
V2 = a 5 membered ring system which may incorporate up to 4 hetero atoms which may be N, N optionally substituted with R2, O or S, the ring system being optionally substituted with up to 4 R1 groups;
W = W1 or W2 or W3 and W is substituted with up to 2 X groups;
W1 = V1;
W2 = a fused bicyclic ring system comprising rings of 5 or 6 atoms, which may incorporate up to 4 hetero atoms, which may be N, N optionally substituted with R2, O or S, the system being optionally substituted with up to 7 R1 groups;
W3 = -N(R2)R'2;
R1 = H, OH, alkyl, alkenyl, alkynyl, alkoxy, alkanol, hydroxyalkoxy, haloalkyl, haloalkoxy, halogen, SH, thioalkyl, cyano (-CN), N(R2)R'2, phenyl, phenyl optionally substituted with up to 5 alkyl groups of 1-3C or up to 5 halogen atoms, benzyl, phenethyl, nitro, -COR3, -R5COR3, -R5SOR3, -R5SO2R3, -SO2N(R2)R'2 or azido;
R2 and R'2 = H, 1-6C alkyl, 3-6C alkyl, 3-6C alkynyl, 2-6C hydroxyalkyl, 2-6C alkoxy, haloalkyl, haloalkenyl, haloalkoxy, benzyl, benzyl optionally substituted with up to 4 R1 groups, phenylethyl,

phenylethyl optionally substituted with up to 4 R1 groups, arylalkyl, and where R2 and R'2 can also be joined to form cyclic structures e.g. pyrrolidine, piperidine, hexahydro-1H-azepine, morpholine or piperazine;

R3 = H, OH, alkyl, alkenyl, alkynyl, alkoxy, alkanol, hydroxyalkoxy, -R4N(R2)R'2, mesyl, trifluoromesyl, -NHSO2CH3 or -NHSO2CF3;

R4 = a bond, alkyl, alkenyl or alkynyl;

X = a bond, -R4N(R2)R4-, -R4N=NR4-, -R4N(R2)-N(R2)R4-, -R4OR4-, -R4SR4, -R5-, -R5O-, -R5S-, -R5N(R2)-, -SO-, sulfonyl (-SO2-), -CO-, -CONH-, -NHCONH-, -NHCO-, -CONHCO-, -CON(R2)-, -R5COR5-, -R5COR5N(R2)R5-, -N(R2)CO- or -R4N(R2)R4COR4-;

R5 = alkyl, alkenyl, alkynyl, alkoxy, alkanol, hydroxyalkoxy;

Y = Y1, Y2 or Y3 and Y is substituted with at least 2, but optionally up to 4 X linking groups;

Y1 = a fused bicyclic ring system comprising rings of 5 or 6 atoms which may incorporate up to 4 hetero atoms, which may be N, N substituted with R2, O or S, the ring system optionally incorporating a sulfoxide (SO), sulfone (SO2) or carbonyl (CO) group and optionally up to 7 R1 groups;

Y2 = a 6:6:6 or a 6:5:6 fused tricyclic system which may incorporate up to 4 hetero atoms which may be N, N optionally substituted with R2, O or S, and the ring system optionally incorporating SO, SO2 or CO, and the ring system being substituted with at least 2, optionally up to 4 X linking groups and optionally up to 7 R1 groups;

Y3 = V1;

Z = -R6COOH, -R6SO3H, -R6NO2, -R6SO2H, -R6SO2NHR2, -R7SO2NHCOR4-N-trifluoromesylsulfonamidate, -OH, -2-yl-hydroxyethanoic acid (-CH(OH)COOH), -3-yl-2-hydroxypropanoic acid (-CH2CH(OH)COOH), -2-yl-2-hydroxypropanoic acid (-CH(CH3)(OH)COOH), -3-yl-2,3-dihydroxypropanoic acid (-CH(OH)CH(OH)COOH), -2-yl-2,3-dihydroxypropanoic acid (-C(CH2(OH))(OH)COOH), -3-yl-2-hydroxypropan-3-one-1-oic acid (-COCH(OH)COOH), 2-yl-2-hydroxypropandioic acid (-C(COOH)(OH)COOH), -2-yl-propandioic acid (-C(COOH)(H)COOH), -4-yl-2-hydroxybutan-4-one-1-oic acid (-COCH2CH(OH)COOH, 2-yl-2-hydroxybutan-1,4-dioic acid (-C(OH)(COOH)CH2COOH), 3-yl-2-hydroxybutan-1,4-dioic acid (-CH(CH(OH)COOH)COOH), 5-yl-tetrazole, CO-NH-CN, P(=O)(OH)(OR4), P(=O)(OH)-NH2 or a group of formula (i) or (ii);

R6 = a bond, alkyl, alkenyl, alkynyl, alkoxy, -CO(CH2)n-, alkanoic, alkenoic or alkynoic, and

n = 0-4;

with the exception that where W1 is an optionally substituted phenyl then Y1 cannot be an optionally substituted phenyl.

The full definitions are given in the DEFINITIONS (Full Definitions) Field.

(3) a method for identifying a **non-peptidyl compound** possessing ionic and hydrophobic chemical moieties spatially located so as to mimic particular ionic and hydrophobic amino acid residues of **insulin** which are associated with the binding of **insulin** to its receptor, comprising: (a) comparing the 3-dimensional structure of the **non-peptidyl compound** with a 3-dimensional pharmacophore of an active site of **insulin**; and (b) selecting a **non-peptidyl compound** with ionic and hydrophobic chemical moieties spatially located so as to mimic the site.

ACTIVITY - Antidiabetic.

MECHANISM OF ACTION - Insulin agonists and antagonists.

USE - The compounds are used as biological modulators of insulin activity or insulin-related activity. Insulin-related ailments include ailments which are related to decreased secretion of insulin, decreased responsiveness of cells to insulin, or increased secretion of insulin, and may including e.g. ailments such as diabetes mellitus (types 1 and 2), insulinomas, insulin and hypoglycemic drug overdose, gastric dumping

syndrome and congenital hyperinsulinism. In addition, insulin and glucose therapy leads to improved cognition in Alzheimer's disease patients. They can be used to treat e.g. humans, farm animals or household pests.
Dwg.0/65

ACCESSION NUMBER: 2000-338749 [29] WPIDS
DOC. NO. CPI: C2000-102744
TITLE: Use of non-peptide modulators of **insulin** action for treating e.g. diabetes mellitus, insulinomas, **insulin** and hyperglycemic drug overdose, gastric dumping syndrome and congenital hyperinsulinism.
DERWENT CLASS: B04 B05 C03
INVENTOR(S): HELMERHORST, E; PLEWRIGHT, B S
PATENT ASSIGNEE(S): (UYCU-N) UNIV CURTIN TECHNOLOGY
COUNTRY COUNT: 90
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2000016798	A1	20000330	(200029)*	EN	
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ TZ UG ZW					
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW					
AU 9960707	A	20000410	(200035)		
EP 1115422	A1	20010718	(200142)	EN	
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI					

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2000016798	A1	WO 1999-AU786	19990917
AU 9960707	A	AU 1999-60707	19990917
EP 1115422	A1	EP 1999-947113	19990917
		WO 1999-AU786	19990917

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 9960707	A	Based on	WO 200016798
EP 1115422	A1	Based on	WO 200016798

PRIORITY APPLN. INFO: AU 1998-6091 19980922

L2 ANSWER 3 OF 23 WPIDS (C) 2002 THOMSON DERWENT
TI Purification of molecules, e.g. peptides.
AN 1999-302984 [25] WPIDS
AB WO 9921889 A UPAB: 19990630
NOVELTY - A process for purifying a molecule selected from a peptide, a polypeptide, and a biologically active **non-peptidyl compound** comprising the elution of the molecule from the column with a buffer containing hexylene glycol, is new.
USE - The method is specifically used for purifying biopharmaceuticals.
ADVANTAGE - While ethanol, methanol, isopropanol, and, in particular, acetonitrile, used in prior art purification, often provide good protein separations using reversed-phase liquid chromatography, they are flammable solvents (acetonitrile has a flashpoint of about 15 deg. C), and using

them at large scale requires expensive non-flammable-capable equipment and facilities. Furthermore, acetonitrile is a denaturant and is toxic to the environment. The new method purifies molecules by reversed-phase liquid chromatography using the non-flammable eluent hexylene glycol rather than a flammable eluent. Hexylene glycol, with a flashpoint of about 93 deg. C, produced essentially the same yield, purity, and throughput as acetonitrile and with less denaturing effect.

ACCESSION NUMBER: 1999-302984 [25] WPIDS
DOC. NO. CPI: C1999-088940
TITLE: Purification of molecules, e.g. peptides.
DERWENT CLASS: B04 D16
INVENTOR(S): FAHRNER, R L; REIFSNYDER, D
PATENT ASSIGNEE(S): (GETH) GENENTECH INC
COUNTRY COUNT: 84
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9921889	A1	19990506	(199925)*	EN	47
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW					
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW					
AU 9910725	A	19990517	(199939)		
ZA 9809424	A	20000628	(200037)		44
EP 1025126	A1	20000809	(200039)	EN	
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE					
AU 740665	B	20011108	(200176)		
JP 2001521044	W	20011106	(200203)		62

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9921889	A1	WO 1998-US21238	19981008
AU 9910725	A	AU 1999-10725	19981008
ZA 9809424	A	ZA 1998-9424	19981015
EP 1025126	A1	EP 1998-953320	19981008
		WO 1998-US21238	19981008
AU 740665	B	AU 1999-10725	19981008
JP 2001521044	W	WO 1998-US21238	19981008
		JP 2000-517996	19981008

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 9910725	A	Based on	WO 9921889
EP 1025126	A1	Based on	WO 9921889
AU 740665	B	Previous Publ.	AU 9910725
		Based on	WO 9921889
JP 2001521044	W	Based on	WO 9921889

PRIORITY APPLN. INFO: US 1997-957760 19971024

L2 ANSWER 4 OF 23 USPATFULL
TI DNA encoding a mammalian receptor (fb41a) and uses thereof
AB This invention provides an isolated nucleic acid encoding a mammalian fb41a receptor, a purified mammalian fb41a receptor, vectors comprising isolated nucleic acid encoding a mammalian fb41a receptor, cells

comprising such vectors, antibodies directed to a mammalian fb41a receptor, nucleic acid probes useful for detecting nucleic acid encoding
a mammalian fb41a receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian fb41a receptor, transgenic, nonhuman animals which express DNA encoding a normal or mutant mammalian fb41a receptor, methods of isolating a mammalian fb41a receptor, methods of treating an abnormality that is linked to the activity of the mammalian fb41a receptor, as well as methods of determining binding of compounds to mammalian fb41a receptors.

ACCESSION NUMBER:	2002:295330 USPATFULL
TITLE:	DNA encoding a mammalian receptor (fb41a) and uses thereof
INVENTOR(S):	Bard, Jonathan A., Doylestown, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002165380	A1	20021107
APPLICATION INFO.:	US 2001-925922	A1	20010809 (9)

RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1998-210279, filed on 10 Dec 1998, ABANDONED
DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	John P. White, Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, NY, 10036
NUMBER OF CLAIMS:	140
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	10 Drawing Page(s)
LINE COUNT:	3039

L2 ANSWER 5 OF 23 USPATFULL
TI Novel interleukin - 1 Hy2 materials and methods
AB The present invention provides machine readable storage media comprising
a three-dimensional representation of Interleukin-1 Hy2 (IL-1Hy2), useful for designing and producing modulators of its activity and IL-1 Hy2 variants, and therapeutic uses thereof. The present invention also provides novel nucleic acids encoding IL-1 Hy2, the novel polypeptides encoded by these nucleic acids and uses of these and related products.

ACCESSION NUMBER:	2002:280564 USPATFULL
TITLE:	Novel interleukin - 1 Hy2 materials and methods
INVENTOR(S):	Ballinger, Dennis, Menlo Park, CA, UNITED STATES Ford, John E., San Diego, CA, UNITED STATES Ho, Alice Suk-Yue, Palo Alto, CA, UNITED STATES Lin, Haishan, Castro Valley, CA, UNITED STATES Pace, Ann, Scotts Valley, CA, UNITED STATES Mize, Nancy K., Mountain View, CA, UNITED STATES Halley-Vicente, Dana, San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002156009	A1	20021024
APPLICATION INFO.:	US 2001-3671	A1	20011102 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-245346P	20001102 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	Sharon M. Sintich, Marshall, Gerstein & Borun, 6300 Sears Tower, 223 South Wacker Drive, Chicago, IL, 60606-6357

NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: [redacted]0 Drawing Page(s)
LINE COUNT: 9665

L2 ANSWER 6 OF 23 USPATFULL
TI Methods of identifying compounds that bind to SNORF25 receptors
AB This invention provides isolated nucleic acids encoding mammalian SNORF25 receptors, purified mammalian SNORF25 receptors, vectors comprising nucleic acid encoding mammalian SNORF25 receptors, cells comprising such vectors, antibodies directed to mammalian SNORF25 receptors, nucleic acid probes useful for detecting nucleic acid encoding mammalian SNORF25 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding mammalian SNORF25 receptors, transgenic, nonhuman animals which express DNA encoding normal or mutant mammalian SNORF25 receptors, methods of isolating mammalian SNORF25 receptors, methods of treating an abnormality that is linked to the activity of the mammalian SNORF25 receptors, as well as methods of determining binding of compounds to mammalian SNORF25 receptors, methods of identifying agonists and antagonists of SNORF25 receptors, and agonists and antagonists so identified.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:275908 USPATFULL
TITLE: Methods of identifying compounds that bind to SNORF25 receptors
INVENTOR(S): Bonini, James A., Oakland, NJ, United States
Borowsky, Beth E., Montclair, NJ, United States
Adham, Nika, Ridgewood, NJ, United States
Boyle, Noel, Cliffside Park, NJ, United States
Thompson, Thelma O., Passaic Park, NJ, United States
PATENT ASSIGNEE(S): Synaptic Pharmaceutical Corporation, Paramus, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6468756	B1	20021022
APPLICATION INFO.:	US 2000-641259		20000817 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 2000-US4413, filed on 22 Feb 2000 Continuation of Ser. No. US 1999-387699, filed on 13 Aug 1999, now patented, Pat. No. US 6221660, issued on 24 Apr 2001 Continuation-in-part of Ser. No. US 1999-255376, filed on 22 Feb 1999, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Spector, Lorraine
ASSISTANT EXAMINER: O'Hara, Eileen B.
LEGAL REPRESENTATIVE: White, John P., Cooper & Dunham LLP
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 24 Drawing Figure(s); 20 Drawing Page(s)
LINE COUNT: 4506
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 7 OF 23 USPATFULL
TI DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof
AB This invention provides an isolated nucleic acid encoding a human MCH1 receptor, a purified human MCH1 receptor, vectors comprising isolated nucleic acid encoding a human MCH1 receptor, cells comprising such vectors, antibodies directed to a human MCH1 receptor, nucleic acid probes useful for detecting nucleic acid encoding human MCH1 receptors,

antisense oligonucleotides complementary to unique sequences of nucleic acid encoding human MCH1 receptors, transgenic, nonhuman animals which express DNA encoding a normal or mutant human MCH1 receptor, methods of isolating a human MCH1 receptor, methods of treating an abnormality that
is linked to the activity of a human MCH1 receptor, as well as methods of determining binding of compounds to mammalian MCH1 receptors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2002:206609 USPATFULL
TITLE:	DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof
INVENTOR(S):	Salon, John A., Santa Paula, CA, UNITED STATES Laz, Thomas M., Parlin, NJ, UNITED STATES Nagorny, Raisa, Fair Lawn, NJ, UNITED STATES Wilson, Amy E., Woodstock, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002111306	A1	20020815
APPLICATION INFO.:	US 2001-885478	A1	20010620 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 1999-US31169, filed on 30 Dec 1999, UNKNOWN Continuation-in-part of Ser. No. US 1999-244426, filed on 10 Feb 1999, GRANTED, Pat. No. US 6306346

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	John P. White, Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, NY, 10036
NUMBER OF CLAIMS:	168
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	15 Drawing Page(s)
LINE COUNT:	4491

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 8 OF 23 USPATFULL

TI Methods of screening for compounds which bind to a human SNORF36A receptor

AB This invention provides isolated nucleic acids encoding mammalian SNORF36 receptors, purified mammalian SNORF36 receptors, vectors comprising nucleic acid encoding mammalian SNORF36 receptors, cells comprising such vectors, antibodies directed to mammalian SNORF36 receptors, nucleic acid probes useful for detecting nucleic acid encoding mammalian SNORF36 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding mammalian SNORF36 receptors, transgenic, nonhuman animals which express DNA encoding normal or mutant mammalian SNORF36 receptors, methods of isolating mammalian SNORF36 receptors, methods of treating an abnormality that is linked to the activity of the mammalian SNORF36 receptors, as well as methods of determining binding of compounds to mammalian SNORF36 receptors, methods of identifying agonists and antagonists of SNORF36 receptors, and agonists and antagonists so identified.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2002:160538 USPATFULL
TITLE:	Methods of screening for compounds which bind to a human SNORF36A receptor
INVENTOR(S):	Borowsky, Beth E., Montclair, NJ, United States Ogozalek, Kristine L., Rochelle Park, NJ, United States Lakhlani, Parul P., Paramus, NJ, United States Adham, Nika, Ridgewood, NJ, United States

PATENT ASSIGNEE(S): Synaptic Pharmaceutical Corporation, Paramus, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6413731	B1	20020702
APPLICATION INFO.:	US 2000-518914		20000303 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-303593, filed on 3 May 1999, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Mertz, Prema
LEGAL REPRESENTATIVE: White, John P., Cooper & Dunham LLP
NUMBER OF CLAIMS: 36
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 42 Drawing Figure(s); 35 Drawing Page(s)
LINE COUNT: 4332
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 9 OF 23 USPATFULL
TI Compounds and methods for modulating junctional adhesion molecule-mediated functions
AB Methods for using modulating agents to enhance or inhibit junctional adhesion molecule (JAM)-mediated cell adhesion in a variety of in vivo and in vitro contexts are provided. The modulating agents comprise at least one JAM cell adhesion recognition sequence or an antibody or fragment thereof that specifically binds the JAM cell adhesion recognition sequence. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:116254 USPATFULL
TITLE: Compounds and methods for modulating junctional adhesion molecule-mediated functions
INVENTOR(S): Blaschuk, Orest W., Westmount, CANADA
Symonds, James Matthew, Ottawa, CANADA
Gour, Barbara J., Kemptville, CANADA
PATENT ASSIGNEE(S): Adherex Technologies, Inc., Ottawa, CANADA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6391855	B1	20020521
APPLICATION INFO.:	US 1999-324541		19990602 (9)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Saunders, David
ASSISTANT EXAMINER: DeCloux, Amy
LEGAL REPRESENTATIVE: SEED Intellectual Property Law Group PLLC
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 2338
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 10 OF 23 USPATFULL
TI Process for determining the agonist or antagonist of galanin receptor (GALR3)
AB This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor,

cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:75211 USPATFULL
TITLE: Process for determining the agonist or antagonist of galanin receptor (GALR3)
INVENTOR(S): Bard, Jonathan A., Doylestown, PA, United States
Borowsky, Beth, Montclair, NJ, United States
Smith, Kelli E., Wayne, NJ, United States
Branchek, Theresa A., Teaneck, NJ, United States
Gerald, Christophe P. G., Ridgewood, NJ, United States
Jones, Kenneth A., Bergenfield, NJ, United States
PATENT ASSIGNEE(S): Synaptic Pharmaceutical Corporation, Paramus, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6368812	B1	20020409
APPLICATION INFO.:	US 1998-58333		19980409 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 1997-US18222, filed on 9 Oct 1997 Continuation-in-part of Ser. No. US 1997-900230, filed on 23 Jul 1997 Continuation-in-part of Ser. No. US 1997-787261, filed on 24 Jan 1997, now abandoned Continuation-in-part of Ser. No. US 1996-767964, filed on 17 Dec 1996, now abandoned Continuation-in-part of Ser. No. US 1996-728139, filed on 9 Oct 1996, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Pak, Michael
LEGAL REPRESENTATIVE: White, John P., Cooper & Dunham LLP
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Figure(s); 19 Drawing Page(s)
LINE COUNT: 5216
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 11 OF 23 USPATFULL
TI Compounds and methods for modulating nonclassical cadherin-mediated functions
AB Modulating agents for inhibiting or enhancing nonclassical cadherin mediated cell adhesion are provided. The modulating agents comprise one or more of: (a) a peptide sequence that is at least 50% identical to a nonclassical cadherin CAR sequence; (b) a non-peptide mimetic of a nonclassical cadherin CAR sequence; (c) a substance, such as an antibody or antigen-binding fragment thereof, that specifically binds a nonclassical cadherin CAR sequence; and/or (d) a polynucleotide encoding a polypeptide that comprises a nonclassical cadherin CAR sequence or analogue thereof. Methods for using such modulating agents for modulating nonclassical cadherin-mediated cell adhesion in a variety of contexts are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:57757 USPATFULL

TITLE: Compounds and methods for modulating nonclassical cadherin-mediated functions
INVENTOR(S): [redacted]laschuk, Orest W., Westmount, CANADA
Gour, Barbara J., Montreal, CANADA
PATENT ASSIGNEE(S): Adherex Technologies, Ottawa, CANADA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6358920	B1	20020319
APPLICATION INFO.:	US 1998-187859		19981106 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1998-73040, filed on 5 May 1998
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Allen, Marianne P.
LEGAL REPRESENTATIVE: Seed Intellectual Property Law Group PLLC
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 23 Drawing Page(s)
LINE COUNT: 5236
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 12 OF 23 USPATFULL
TI DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof
AB This invention provides an isolated nucleic acid encoding a human MCH1 receptor, a purified human MCH1 receptor, vectors comprising isolated nucleic acid encoding a human MCH1 receptor, cells comprising such vectors, antibodies directed to a human MCH1 receptor, nucleic acid probes useful for detecting nucleic acid encoding human MCH1 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding human MCH1 receptors, transgenic, nonhuman animals which express DNA encoding a normal or mutant human MCH1 receptor, methods of isolating a human MCH1 receptor, methods of treating an abnormality that
is linked to the activity of a human MCH1 receptor, as well as methods of determining binding of compounds to mammalian MCH1 receptors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2001:158027 USPATFULL
TITLE: DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof
INVENTOR(S): Salon, John A., Montclair, NJ, United States
Laz, Thomas M., Parlin, NJ, United States
Nagorny, Raisa, Fair Lawn, NJ, United States
Wilson, Amy E., New York, NY, United States
PATENT ASSIGNEE(S): Synaptic Pharmaceutical Corporation, Paramus, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6291195	B1	20010918
APPLICATION INFO.:	US 2000-478602		20000106 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-224426, filed on 31 Dec 1998
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Spector, Lorraine
ASSISTANT EXAMINER: O'Hara, Eileen B.
LEGAL REPRESENTATIVE: White, John P.Cooper & Dunham LLP
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Figure(s); 11 Drawing Page(s)

LINE COUNT: 2920
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 13 OF 23 USPATFULL
TI DNA encoding galanin GALR3 receptors and uses thereof
AB This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2001:152696 USPATFULL
TITLE:	DNA encoding galanin GALR3 receptors and uses thereof
INVENTOR(S):	Bard, Jonathan A., Doylestown, PA, United States Borowsky, Beth, Montclair, NJ, United States Smith, Kelli E., Wayne, NJ, United States Branchek, Theresa A., Teaneck, NJ, United States Gerald, Christophe P. G., Ridgewood, NJ, United States Jones, Kenneth A., Bergenfield, NJ, United States
PATENT ASSIGNEE(S):	Synaptic Pharmaceutical Corporation, Paramus, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6287788	B1	20010911
APPLICATION INFO.:	US 1998-199737		19981125 (9)

RELATED APPLN. INFO.:	Continuation of Ser. No. WO 1997-US18222, filed on 9 Oct 1997 Continuation-in-part of Ser. No. US 1997-900230, filed on 23 Jul 1997 Continuation-in-part of Ser. No. US 1997-787261, filed on 24 Jan 1997, now abandoned Continuation-in-part of Ser. No. US 1996-767964, filed on 17 Dec 1996, now abandoned Continuation-in-part of Ser. No. US 1996-728139, filed on 9 Oct 1996, now abandoned
DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Pak, Michael
LEGAL REPRESENTATIVE:	White, John P.Cooper & Dunham LLP
NUMBER OF CLAIMS:	16
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	21 Drawing Figure(s); 16 Drawing Page(s)
LINE COUNT:	4441

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 14 OF 23 USPATFULL
TI DNA ENCODING GALANIN GALR3 RECEPTORS AND USES THEREOF
AB This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2001:119145 USPATFULL
TITLE: DNA ENCODING GALANIN GALR3 RECEPTORS AND USES THEREOF
INVENTOR(S): BARD, JONATHAN A., DOLYTOWN, PA, United States
BOROWSKY, BETH, MONTCLAIR, NJ, United States
SMITH, KELLI E., WAYNE, NJ, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001009766	A1	20010726
	US 6329197	B2	20011211
APPLICATION INFO.:	US 1997-900230	A1	19970723 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-787261, filed on 24 Jan 1997, ABANDONED Continuation-in-part of Ser. No. US 1996-767964, filed on 17 Dec 1996, ABANDONED Continuation-in-part of Ser. No. US 1996-728139, filed on 9 Oct 1996, ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: COOPER & DUNHAM, 1185 AVE OF THE AMERICAS, NEW YORK, NY, 10036
NUMBER OF CLAIMS: 211
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Page(s)
LINE COUNT: 4388
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 15 OF 23 USPATFULL
TI Purification of molecules
AB A process for purifying molecules from contaminants is provided. In this process a mixture containing the molecule (peptide, polypeptide, or biologically active **non-peptidyl compound**) and its contaminants is loaded onto a reversed-phase liquid chromatography column and the molecule is eluted from the column with a buffer containing hexylene glycol.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2001:117147 USPATFULL
TITLE: Purification of molecules
INVENTOR(S): Fahrner, Robert Lee, San Francisco, CA, United States
Reifsnyder, David, El Cerrito, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6265542	B1	20010724
APPLICATION INFO.:	US 1998-168548		19981008 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-63119P	19971024 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Low, Christopher S. F.
ASSISTANT EXAMINER: Gupta, Anish
LEGAL REPRESENTATIVE: Hasak, Janet E.
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 31 Drawing Figure(s); 12 Drawing Page(s)
LINE COUNT: 1560

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 16 OF 23 USPATFULL
TI DNA encoding mammalian neuropeptides FF (NPFF) receptors and uses thereof
AB This invention provides isolated nucleic acids encoding mammalian NPFF receptors, purified mammalian NPFF receptors, vectors comprising nucleic acid encoding mammalian NPFF receptors, cells comprising such vectors, antibodies directed to mammalian NPFF receptors, nucleic acid probes useful for detecting nucleic acid encoding mammalian NPFF receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding mammalian NPFF receptors, transgenic, nonhuman animals which express DNA encoding normal or mutant mammalian NPFF receptors, methods of isolating mammalian NPFF receptors, methods of treating an abnormality that is linked to the activity of the mammalian NPFF receptors, as well as methods of determining binding of compounds to mammalian NPFF receptors, methods of identifying agonists and antagonists of NPFF receptors, and agonists and antagonists so identified.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2001:112510 USPATFULL
TITLE:	DNA encoding mammalian neuropeptides FF (NPFF) receptors and uses thereof
INVENTOR(S):	Gerald, Christophe P. G., Ridgewood, NJ, United States Jones, Kenneth A., Bergenfield, NJ, United States Bonini, James A., Oakland, NJ, United States Borowsky, Beth, Montclair, NJ, United States
PATENT ASSIGNEE(S):	Synaptic Pharmaceutical Corporation, Paramus, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6262246	B1	20010717
APPLICATION INFO.:	US 1999-255368		19990222 (9)

RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1998-161113, filed on 25 Sep 1998, now abandoned
DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Mertz, Prema
ASSISTANT EXAMINER:	Murphy, Joseph F.
LEGAL REPRESENTATIVE:	White, John P.Cooper & Dunham LLP
NUMBER OF CLAIMS:	19
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	27 Drawing Figure(s); 21 Drawing Page(s)
LINE COUNT:	3504

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 17 OF 23 USPATFULL
TI **Insulin**-like growth factor agonist molecules
AB Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2001:97888 USPATFULL
TITLE:	**Insulin**-like growth factor agonist molecules
INVENTOR(S):	Clark, Ross G., Auckland, New Zealand Lowman, Henry B., El Granada, CA, United States Robinson, Iain C. A. F., St. Albans, United Kingdom
PATENT ASSIGNEE(S):	Genentech, Inc., South San Francisco, CA, United States

(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6251865	B1	20010626
APPLICATION INFO.:	US 1998-52888		19980331 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Romeo, David
LEGAL REPRESENTATIVE: Hasak, Janet E.
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 66 Drawing Figure(s); 44 Drawing Page(s)
LINE COUNT: 4925
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 18 OF 23 USPATFULL
TI DNA encoding SNORF25 receptor
AB This invention provides isolated nucleic acids encoding mammalian SNORF25 receptors, purified mammalian SNORF25 receptors, vectors comprising nucleic acid encoding mammalian SNORF25 receptors, cells comprising such vectors, antibodies directed to mammalian SNORF25 receptors, nucleic acid probes useful for detecting nucleic acid encoding mammalian SNORF25 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding mammalian SNORF25 receptors, transgenic, nonhuman animals which express DNA encoding normal or mutant mammalian SNORF25 receptors, methods of isolating mammalian SNORF25 receptors, methods of treating an abnormality that is linked to the activity of the mammalian SNORF25 receptors, as well as methods of determining binding of compounds to mammalian SNORF25 receptors, methods of identifying agonists and antagonists of SNORF25 receptors, and agonists and antagonists so identified.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2001:59682 USPATFULL
TITLE: DNA encoding SNORF25 receptor
INVENTOR(S): Bonini, James A., Oakland, NJ, United States
Borowsky, Beth E., Montclair, NJ, United States
Adham, Nika, Ridgewood, NJ, United States
Boyle, Noel, Cliffside Park, NJ, United States
Thompson, Thelma O., Passaic Park, NJ, United States
PATENT ASSIGNEE(S): Synaptic Pharmaceutical Corporation, Paramus, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6221660	B1	20010424
APPLICATION INFO.:	US 1999-387699		19990813 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-255376, filed on 22 Feb 1999
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Spector, Lorraine
ASSISTANT EXAMINER: O'Hara, Eileen B.
LEGAL REPRESENTATIVE: White, John P.Cooper & Dunham LLP
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 16 Drawing Figure(s); 14 Drawing Page(s)
LINE COUNT: 2877
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 19 OF 23 USPATFULL
TI DNA encoding a an melanin concentrating hormo[redacted]receptor (MCH1) and uses thereof
AB This invention provides an isolated nucleic acid encoding a human MCH1 receptor, a purified human MCH1 receptor, vectors comprising isolated nucleic acid encoding a human MCH1 receptor, cells comprising such vectors, antibodies directed to a human MCH1 receptor, nucleic acid probes useful for detecting nucleic acid encoding human MCH1 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding human MCH1 receptors, transgenic, nonhuman animals which express DNA encoding a normal or mutant human MCH1 receptor, methods of isolating a human MCH1 receptor, methods of treating an abnormality that
is linked to the activity of a human MCH1 receptor, as well as methods of determining binding of compounds to mammalian MCH1 receptors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2001:59638 USPATFULL
TITLE: DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof
INVENTOR(S): Salon, John A., Montclair, NJ, United States
Laz, Thomas M., Parlin, NJ, United States
Nagorny, Raisa, Fair Lawn, NJ, United States
Wilson, Amy E., New York, NY, United States
PATENT ASSIGNEE(S): Synaptic Pharmaceutical Corporation, Paramus, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6221616	B1	20010424
APPLICATION INFO.:	US 2000-478601		20000106 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-224426, filed on 31 Dec 1998
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Spector, Lorraine
ASSISTANT EXAMINER: O'Hara, Eileen B.
LEGAL REPRESENTATIVE: White, John P.Cooper & Dunham LLP
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 2882
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 20 OF 23 USPATFULL
TI DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof
AB This invention provides an isolated nucleic acid encoding a human MCH1 receptor, a purified human MCH1 receptor, vectors comprising isolated nucleic acid encoding a human MCH1 receptor, cells comprising such vectors, antibodies directed to a human MCH1 receptor, nucleic acid probes useful for detecting nucleic acid encoding human MCH1 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding human MCH1 receptors, transgenic, nonhuman animals which express DNA encoding a normal or mutant human MCH1 receptor, methods of isolating a human MCH1 receptor, methods of treating an abnormality that
is linked to the activity of a human MCH1 receptor, as well as methods of determining binding of compounds to mammalian MCH1 receptors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2001:59635 USPATFULL
TITLE: DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof

INVENTOR(S): Salon, John A., Montclair, NJ, United States
az, Thomas M., Parlin, NJ, Uni[redacted] States
agorny, Raisa, Fair Lawn, NJ, United States
Wilson, Amy E., New York, NY, United States
PATENT ASSIGNEE(S): Synaptic Pharmaceutical Corporation, Paramus, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6221613	B1	20010424	
APPLICATION INFO.:	US 1998-224426		19981231	(9)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Spector, Lorraine
ASSISTANT EXAMINER: O'Hara, Eileen B.
LEGAL REPRESENTATIVE: White, John P.Cooper & Dunham LLP
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 2913
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 21 OF 23 USPATFULL
TI DNA encoding a mammalian LPA receptor and uses thereof
AB This invention provides an isolated nucleic acid encoding a mammalian LPA receptor, a purified mammalian LPA receptor, vectors comprising isolated nucleic acid encoding an mammalian LPA receptor, cells comprising such vectors, antibodies directed to a mammalian LPA receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian LPA receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding mammalian LPA receptor, transgenic, nonhuman animals which express DNA encoding a normal or a mutant mammalian LPA receptor, methods of isolating an mammalian LPA receptor, methods of treating an abnormality that is linked to the activity of the mammalian LPA receptor, as well as methods of determining binding of compounds to mammalian LPA receptors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2001:47841 USPATFULL
TITLE: DNA encoding a mammalian LPA receptor and uses thereof
INVENTOR(S): Bard, Jonathan A., Doylestown, PA, United States
PATENT ASSIGNEE(S): Synaptic Pharmaceutical Corporation, Paramus, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6210967	B1	20010403	
APPLICATION INFO.:	US 1997-987943		19971210	(8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Kunz, Gary L.
ASSISTANT EXAMINER: O'Hara, Eileen B.
LEGAL REPRESENTATIVE: White, John P.Cooper & Dunham LLP
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 1807
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 22 OF 23 USPATFULL
TI Compounds and methods for modulating tissue permeability
AB Methods for using modulating agents to enhance or inhibit occludin-mediated cell adhesion in a variety of in vivo and in vitro

contexts are provided. Within certain embodiments, the modulating agents
may be used to rease vasopermeability. The modulating agents comprise
at least one occludin cell adhesion recognition sequence or an antibody or fragment thereof that specifically binds the occludin cell adhesion recognition sequence. Modulating agents may additionally comprise one or
more cell adhesion recognition sequences recognized by other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2000:113775 USPATFULL
TITLE:	Compounds and methods for modulating tissue permeability
INVENTOR(S):	Blaschuk, Orest W., Westmount, Canada Symonds, James Matthew, Ottawa, Canada Gour, Barbara J., Kemptville, Canada
PATENT ASSIGNEE(S):	Adherex Technologies Inc., Ottawa, Canada (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6110747		20000829
APPLICATION INFO.:	US 1998-222373		19981229 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-1511, filed on 31 Dec 1997		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Davenport, Avis M.		
LEGAL REPRESENTATIVE:	Seed IP Law Group PLLC		
NUMBER OF CLAIMS:	9		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	9 Drawing Figure(s); 12 Drawing Page(s)		
LINE COUNT:	2887		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 23 OF 23 USPATFULL

TI Method of identifying ligands which bind recombinant galanin receptor (GALR2)

AB This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising an isolated nucleic acid encoding a galanin receptor, cells comprising such vectors, antibodies directed to the galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding galanin receptors, antisense oligonucleotides complementary to unique sequences of a nucleic acid encoding a galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant galanin receptor, as well as methods of determining binding of compounds to the galanin receptor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	1999:132514 USPATFULL
TITLE:	Method of identifying ligands which bind recombinant galanin receptor (GALR2)
INVENTOR(S):	Smith, Kelli E., Wayne, NJ, United States Gerald, Christophe P. G., Ridgewood, NJ, United States Weinshank, Richard L., Teaneck, NJ, United States Linemeyer, David, Westfield, NJ, United States Branchek, Theresa, Teaneck, NJ, United States Forray, Carlos, Paramus, NJ, United States
PATENT ASSIGNEE(S):	Synaptic Pharmaceutical Corporation, Paramus, NJ,

United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5972624		19991026
APPLICATION INFO.:	US 1996-626685		19960401 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1996-590494, filed on 24 Jan 1996, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Feisee, Lila
ASSISTANT EXAMINER: Pak, Michael
LEGAL REPRESENTATIVE: White, John P.Cooper & Dunham LLP
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Figure(s); 16 Drawing Page(s)
LINE COUNT: 2695
CAS INDEXING IS AVAILABLE FOR THIS PATENT.